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Insulin-like growth factor I (IGF-I) stimulates cell proliferation and can enhance the development of tumours in different organs.
Epidemiological studies have shown that an elevated level of circulating IGF-I is associated with increased risk of breast cancer, as well
as of other cancers. Most of circulating IGF-I is bound to an acid-labile subunit and to one of six insulin-like growth factor binding
proteins (IGFBPs), among which the most important are IGFBP-3 and IGFBP-1. Polymorphisms of the IGF1 gene and of genes
encoding for the major IGF-I carriers may predict circulating levels of IGF-I and have an impact on cancer risk. We tested this
hypothesis with a case–control study of 807 breast cancer patients and 1588 matched control subjects, nested within the European
Prospective Investigation into Cancer and Nutrition. We genotyped 23 common single nucleotide polymorphisms in IGF1, IGFBP1,
IGFBP3 and IGFALS, and measured serum levels of IGF-I and IGFBP-3 in samples of cases and controls. We found a weak but
significant association of polymorphisms at the 50 end of the IGF1 gene with breast cancer risk, particularly among women younger
than 55 years, and a strong association of polymorphisms located in the 50 end of IGFBP3 with circulating levels of IGFBP-3, which
confirms previous findings. Common genetic variation in these candidate genes does not play a major role in altering breast cancer
risk in Caucasians.
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Insulin-like growth factor-I (IGF-I) is a peptide growth factor that
exerts mitogenic and metabolic activities that are regulators of
growth, survival and cell differentiation in a number of cell and
tissue types. A number of epidemiologic studies have shown a
direct association between circulating IGF-I levels and breast
cancer risk, especially in young women (Peyrat et al, 1993; Bruning
et al, 1995; Bohlke et al, 1998; Hankinson et al, 1998; Toniolo et al,
2000; Muti et al, 2002; Yu et al, 2002). Elevated circulating IGF-I
also has been found to be a potential cancer risk factor for cancers
of other organs, such as the prostate (Mantzoros et al, 1997; Chan
et al, 1998; Wolk et al, 1998; Stattin et al, 2000) and the colorectum
(Ma et al, 1999; Giovannucci et al, 2000; Kaaks et al, 2000;
Palmqvist et al, 2002).
Most of the circulating IGF-I originates from the liver. In the
circulation, it is either free or bound to one of six high-affinity
binding proteins, which regulate IGF-I activity. About 90% of the
circulating IGF-I is bound to insulin-like binding protein-3
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s(IGFBP-3), which forms a ternary complex with an acid-labile
subunit (ALS). The smaller complexes are able to pass the vascular
endothelial barrier and therefore may be important modulators of
IGF-I activity at the cellular level (Jones et al, 1993; Rajaram et al,
1997). There is physiologic evidence of a role for IGFBPs to work
either in an IGF-I-dependent, such as increasing the half-life
of IGF-I and modulating access to the IGF-I receptor, or IGF-I-
independent fashion by mediating their effects directly on target
cells, where they generally have a proapoptotic role (Jones et al,
1993; Perks et al, 1999; Gleeson et al, 2001; Mohan and Baylink,
2002).
While nutrition is an important determinant of circulating IGF-I
levels (Thissen et al, 1994; Kaaks and Lukanova, 2001), heritability
studies have shown that up to 40–60% of the variation in
circulating IGF-I levels is determined by genetic factors (Harrela
et al, 1996; Verhaeghe et al, 1996; Hong et al, 1997; Hall et al,
1999). So far, however, only few studies have been conducted to
identify specific gene variants that influence circulating IGF-I
levels, even though such research is currently intensifying
(Hasegawa et al, 2000; Lopez-Bermejo et al, 2000; Jernstrom
et al, 2001a; Vaessen et al, 2001).
For the present study, we focused on 23 common single
nucleotide polymorphisms (SNPs) that we estimated would have
the highest chance of having an impact on either the expression
or function of IGF-I and of molecules (IGFBP-1, IGFBP-3 and
IGFALS) involved in IGF-I transport. We conducted a case–
control study of 807 breast cancer patients and 1588 matched
control subjects, nested within the cohorts of the European
Prospective Investigation into Cancer and Nutrition (EPIC) (Riboli
et al, 2002; Bingham and Riboli, 2004), and examined relationships
of these polymorphisms with circulating IGF-I and IGFBP-3 levels,
as well as breast cancer risk.
MATERIAL AND METHODS
The EPIC study
The EPIC cohort consists of about 370000 women and 150000
men, aged 35–69 years, recruited between 1992 and 1998
in 23 research centres in 10 Western European countries. Although
detailed information on ethnicity of EPIC subjects is not available,
in practice, recruitment has not been conducted in large
cosmopolitan urban areas; therefore, owing to the current
ethnic composition of the regions involved in the study,
we estimate that the vast majority (497%) of subjects recruited
in the EPIC cohort are of Caucasian origin. All EPIC study
subjects provided anthropometric measurements (height,
weight, waist and hip circumferences) and extensive, standardised
questionnaire information about medical history, diet,
physical activity, smoking and other lifestyle factors. Women
also answered questions about menstrual and reproductive
history, hysterectomy, ovariectomy and use of exogenous hor-
mones for contraception or treatment of menopausal symptoms.
In addition, about 240000 women and 140000 men provided a
blood sample.
Cases of cancer occurring after recruitment into the cohort
are identified through local and national cancer registries in
seven of the 10 countries, and in France, Germany and Greece
by a combination of contacts with national health insurances
and/or active follow-up through the study subjects or their next
of kin. Follow-up on vital status, to monitor the population
remaining at risk for cancer, is achieved through record linkage
with mortality registries. In all EPIC study centres, cancer
diagnosis is confirmed through comprehensive review of patho-
logy reports, and checks for completeness of follow-up are made
periodically. A fully detailed description of the EPIC study has
been published elsewhere (Riboli et al, 2002; Bingham and Riboli,
2004).
Selection of case and control subjects
Cases and controls from the present study were from 16 of the 23
EPIC recruitment centres, in seven of the 10 countries participa-
ting in EPIC (UK, Germany, The Netherlands, France, Spain, Italy
and Greece), and were part of a larger nested case–control study
on serum hormones and breast cancer risk, reported in detail
elsewhere (Kaaks et al, 2005a,b; Rinaldi et al, manuscript
submitted).
Case subjects were selected among women who developed breast
cancer after their recruitment into the EPIC study, and before the
end of the study period, for each study centre defined by the latest
end-date of follow-up. Women who used any hormone replace-
ment therapy at the time of blood donation, or any exogenous
hormones for contraception or medical purposes, and who had
previous diagnosis of cancer (except non-melanoma skin cancer)
were excluded from the study, because each of these various
factors could have altered circulating hormone levels.
For each case subject with breast cancer, two control subjects
were chosen at random from among cohort members alive and free
of cancer (except non-melanoma skin cancer) at the time of
diagnosis of the index case. Control subjects were matched to the
cases by study centre where the subjects were enrolled in the
cohort, as well as by menopausal status (premenopausal,
postmenopausal, perimenopausal/undefined), age (76 months)
at enrolment, follow-up time, fasting status, time of the day of
blood donation and phase of the menstrual cycle for premeno-
pausal women (assessed according to criteria defined by Kaaks
et al).
Approval for the study was given by the relevant Ethical
Committees, both at the IARC and in each of the EPIC recruitment
centres.
Identification and selection of SNPs
We collected data on polymorphisms from publicly available
databases, such as dbSNP (http://www.ncbi.nlm.nih.gov/SNP/),
SNPper (http://snpper.chip.org/) and Frequency Finder (http://
bluegenes.bsd.uchicago.edu/frequencyfinder/). We complemented
database searches with literature review and, for IGFBP1 and
IGFBP3, with analysis of 95 subjects from the EPIC population by
denaturing high-performance liquid chromatography (DHPLC;
Xiao and Oefner, 2001).
To be included in the study, polymorphisms had to be located in
exons (including untranslated regions), exon–intron junctions or
promoter regions of a gene of interest, or otherwise should be
within intronic regions that showed greater than 80% homology
between human and mouse (as reported by the UCSC Genome
Browser, http://genome.ucsc.edu/), and thus were likely to harbour
regulatory sequences. We included only polymorphisms whose
existence in Caucasians is documented, either according to
literature data or to our own experimental analysis by DHPLC.
All new SNPs identified in our laboratory by DHPLC searches have
been deposited in dbSNP (http://www.ncbi.nlm.nih.gov/SNP).
Among all polymorphisms thus identified, we retained only those
with a minor allele frequency X5% in Caucasians or those that
result in an amino-acid change and had a minor allele frequency
X1%. Finally, we particularly favoured the inclusion of all
polymorphisms that were previously reported in the literature to
be associated with cancer risk and/or levels of circulating
hormones. In total, this strategy led to a list of 26 SNPs for
genotyping.
Genotyping
Buffy coat samples for the study subjects were retrieved from the
EPIC biorepository and DNAs were extracted on an Autopure
instrument (Gentra Systems, Minneapolis, MN, USA) with Pure-
gene chemistry (Gentra Systems, Minneapolis, MN, USA).
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sGenotyping was performed by the 50 nuclease assay (TaqMan).
The order of DNAs from cases and controls was randomised on
PCR plates in order to assure that an equal proportion of cases and
controls could be analysed simultaneously. TaqMan probes were
synthesised by either Applied Biosystems, Foster City, CA, USA
(with MGB chemistry) or Proligo, Paris, France (with or without
LNA chemistry). Sequences of primers and probes are reported
in Supplementary Table 1. For one SNP, a genotyping assay could
not be designed and for two more SNPs, TaqMan assays were
generated but provided poor genotyping results. This left 23
polymorphisms that were genotyped on the DNAs of cases and
controls (Table 1). The reaction mix included 10ng genomic DNA,
5pmol of each primer, 1pmol of each probe and 2.5mlo f2  
master mix (Applied Biosystems) in a final volume of 5ml. The
thermocycling included 50 cycles with 30s at 951C followed by 60s
at 601C. PCR plates were read on an ABI PRISM 7900HT
instrument (Applied Biosystems). Laboratory personnel was kept
blinded to case–control status throughout the study. Genotyping
call rates ranged between 95.27 and 99.44%. The distributions of
genotypes of all polymorphisms were in agreement with the
Hardy–Weinberg equilibrium (calculated in the control group).
Repeated quality control genotypes (8% of the total) showed
greater than 99% concordance for all assays.
Hormone measurements
Measurements of IGF-I and IGFBP-3 were performed in the
laboratory of the Hormones and Cancer, at IARC, using enzyme-
linked immunosorbent assays from Diagnostic System Labora-
tories (DSL, Webster, TX, USA). The IGF-I assays included an
acid–ethanol precipitation step to eliminate IGF-I binding
proteins, to avoid their interference with the IGF-I measurement.
Measurements were performed on never thawed serum sample
aliquots. The mean intra- and inter-batch coefficients of variation
were 6.2 and 16.2% respectively for IGF-I, and 7.2 and 9.7%
respectively for IGFBP-3.
Statistical analysis
Individual haplotype frequencies (i.e. estimated numbers of copies
of haplotypes) were reconstructed using the program ‘tagSNPs’
(http://www-rcf.usc.edu/~stram/tagSNPs.html; Stram et al,
2003a,b). This program calculates, for each individual, the
expected numbers of copies (‘dosages’) of each of the haplotypes
compatible with the individuals’ SNP genotypes. This method
takes into account uncertainties in the haplotype reconstruction
for individuals who are heterozygous for two or more of the SNPs
within a given gene. Haplotype dosages are estimated from the
individuals’ SNP genotype data and from overall haplotype
frequency estimates for the full study population (cases and
controls combined) estimated by a maximum likelihood method.
For each haplotype, the dosage values range from 0 to 2.0 (alleles),
and for each individual these dosage values add up to a total value
of 2.0 across all possible haplotypes.
All association analyses, at the level of individual SNPs or gene
loci, were performed under different assumed modes of inheri-
tance of effect – dominant, recessive or codominant – associated
with alleles. In the ‘dominant’ model, circulating peptide levels or
disease risks were compared between subjects carrying at least one
copy of the rare allele and those who had none; in the ‘recessive’
model, the comparison was between those who were homozygous
for the rare allele and all others; in the ‘codominant’ model,
individuals’ peptide levels or the logarithm of disease risk were
linearly related to the number of copies of an allele (0, 1 or 2 for
SNP alleles, or dosages for the haplotype) carried by the
individuals. For rare alleles, with a frequency less than 20% (i.e.
a prevalence of homozygous recessive allele carriers less than 4%),
only the dominant model was used. To test whether any
association of gene variants with breast cancer risk could be
mediated by alterations in circulating levels of IGF-I and/or
IGFBP-3, these associations were also estimated with adjustment
for serum peptide levels.
Relationships of polymorphic gene variants with serum levels of
IGF-I and IGFBP-3 were estimated by standard normal regression
models, stratified by EPIC recruitment centre and further adjusted
for age. Relationships of polymorphic variants with breast cancer
risk (odds ratios) were estimated using conditional logistic
regression models, applied on the matched case–control sets.
Both series of analyses were performed at the level of single SNP
loci, as well as at the level of haplotypes (using the haplotype
dosage values). Haplotype analyses were performed at the level of
full gene loci – that is, including haplotypes based on all of the
SNPs in that gene – and for the IGF1 and IGFBP3 genes also at the
level of well-delineated haplotype blocks within a gene. In all
haplotype analyses, the most common haplotype was used as the
reference category.
Adjustment for potentially relevant variables (body mass index,
adult height, total caloric intake) did not alter significantly the
results (data not shown). Exclusion of cases diagnosed within a
year of blood collection also did not have an impact on the results
(data not shown).
Reconstruction of haplotype blocks within each gene was
performed with Haploview (http://www.broad.mit.edu/personal/
jcbarret/haploview; Barrett et al, 2005). Block boundaries were
determined using the criterion of Gabriel et al (2002).
Subgroup analyses on women with a breast cancer diagnosis
either before (45% of the subjects) or after age at diagnosis
of 55 years (the age at which over 99% of women enrolled in the
EPIC cohort declared themselves menopausal) were used to
examine whether associations of gene variants with breast cancer
risk differed between women with cancer at approximately
Table 1 Polymorphisms used in the present study
Polymorphism
a Alleles (major4minor) Position in gene Codon
IGF1
rs35765 C4A Promoter region
rs35767 C4T Promoter region
rs2162679 A4G Intron 1
rs6220 T4C Exon 4; 30 UTR
rs6214 C4T Exon 4; 30 UTR
IGFBP1
rs1995051 G4A Promoter region
rs1065780 G4A Promoter region
rs9658194 C4A Intron 1
rs3828998 T4C Intron 1
rs3793344 A4G Intron 1
rs4988515 C4T Exon 4 Cys230Cys
rs4619 A4G Exon 4 Met253Ile
IGFBP3
rs2132571 G4A Promoter region
rs2132572 G4A Promoter region
rs2854744 C4A Promoter region
rs2471551 G4C Intron 1
P0453
b C4T Exon 4 Thr277Ile
rs2453839 A4G Exon4; 30 UTR
P0448
b T4C Exon4; 30 UTR
rs6670 A4T Exon4; 30 UTR
IGFALS
rs3751893 T4C Exon 2 Asp70Asp
rs17559 C4T Exon 2 Tyr462Tyr
rs2230053 G4A Exon 2 Thr522Thr
UTR¼untranslated region.
aPolymorphisms are identified by their dbSNP accession
number.
bInternal references are used for polymorphisms not present in dbSNP.
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of effect between these two age groups was tested using a w
2 test.
We estimated the false positive reporting probability (FPRP) for
statistically significant observations based on the methods
described by Wacholder et al (2004). Prior probability is likely
to be influenced by the biological knowledge of the gene, the
functional significance of the variants and the available epidemio-
logical evidence. It remains a subjective measure that may vary
from one investigator to another based on the importance they
assign to the different pieces of evidence. For this reason, we have
calculated FPRP for a range of prior probabilities from 50 to 0.1%.
We considered that a prior probability of 50% might be acceptable
when there was a very strong biological plausibility with consistent
epidemiological evidence (i.e. the association between SNPs in
the 50 part of IGFBP3 and IGFBP-3 level), and a prior probability of
0.1% may be appropriate when the biological knowledge and
epidemiological data were both inadequate (i.e. the majority of
other SNPs, whose exact function is not known, and epidemiolo-
gical data do not exist).
RESULTS
A total of 807 incident cases of breast cancer from the EPIC cohort
and 1588 matched controls were included in our study. The mean
age of study subjects at blood donation was 55 years (5th–95th
percentile: 39.9–68.7 years). For cases, the mean age at diagnosis
was 57 years (5th–95th percentile: 42–71 years). Based on the
questionnaire data, 32% of the subjects were premenopausal at
blood donation, 10% were perimenopausal or of unknown
menopausal status and 58% were postmenopausal. Cases had a
significantly lower number of full-term pregnancies than controls
(means: 2.35 vs 2.47, P¼0.02) and were significantly older at first
full-term pregnancy (26 vs 25.5 years in controls, P¼0.02). Age at
menarche did not differ between cases and controls, nor did body
mass index. Serum levels of IGF-I adjusted for age and centre
were not significantly different between cases and controls (means:
248.7 vs 244.4ngml
 1, P¼0.15), nor for the subgroups subjects
with cancer diagnosis before or at the age of 55 years (272.0 vs
270.7; P¼0.79), or after (224.0 vs 217.5; P¼0.08). Case subjects
did show higher mean levels of serum IGFBP-3 than controls
(means: 3422 vs 3361ngml
 1, P¼0.04). The latter difference,
however, was due mostly to the subgroup with cancer diagnosis
after age 55 years (3473 vs 3378; P¼0.02), and was not clearly
visible among the younger women (3190 vs 3173; P¼0.66). Details
on the relationships of IGF-I and IGFBP-3 with breast cancer risk,
with an extended series of 1195 beast cancer cases and 2321 control
subjects, will be reported elsewhere (Rinaldi et al, manuscript
submitted).
The number of SNPs typed per gene ranged from three for
IGFALS to eight for IGFBP3. Results of associations between
individual SNPs and cancer risk and circulating IGF-I and IGFBP-3
levels are reported in Table 2. Supplementary Tables 2a–f report
results of analyses relating hormone levels and breast cancer risk
to haplotypes.
In the IGF1 gene, we noted an association of the rs2162679 SNP,
with the G/G genotype being associated with a reduction in risk
of breast cancer (P¼0.05) and also a modest effect in the
heterozygote (P-trend for codominant model¼0.03). Interestingly,
when the cases were stratified by age of onset (less than 55 years
old or greater than or equal to 55 years old), this reduction appears
to be confined to breast cancer cases with an early age of diagnosis,
at 55 years or before, and was strongest (odds ratio 0.17,
confidence interval 0.07–0.56) in the homozygous G/G
(P¼0.005). This association was also found to be statistically
significant under the dominant (P¼0.01) and codominant
(P¼0.002) models. Linkage disequilibrium (LD) reconstruction
of this region shows that there is strong LD between the rs2162679
and the two surrounding SNPs, rs35765 and rs35767. As expected,
rs35767 and rs35765 also showed a reduction in breast cancer risk
among the entire set, although the only statistically significant
result was seen for rs35767 when testing for trend (P¼0.04).
However, as with rs2162679, the reduction effect was statistically
significant in both rs35767 and rs35765 for the breast cancer cases
diagnosed at age 55 years or before. Haplotype analysis of the IGF1
data showed only an association between one rare haplotype and
cancer risk (Supplementary Table 2). When we analysed the block
structure of IGF1, based on our control genotypes, we noted a clear
haplotype block that contains rs35765, rs35767 and rs2162679
(Figure 1A). When we restricted our haplotype analysis to only
this block, we observed an association between cancer risk and
haplotype hCTG, which has a frequency of 4% and includes the
rare alleles of rs35767 and rs2162679. This association was not
stronger than that seen with the individual SNPs (Supplementary
Table 2).
We also noted a significant decrease in circulating IGFBP-3
levels with the rare homozygous states for both rs2162679 and
rs35767 (again representing the LD between these markers). In
contrast to the association of breast cancer risk, with the same
markers, this effect appeared restricted to a later age of onset in
our age-stratified analysis. When we performed the same analysis
by using the haplotype block that spans the 50 end of the gene
and includes rs2162679 and rs35767, the same haplotype that is
associated with reduced cancer risk appeared also to be strongly
associated with decreased IGFBP-3 levels (Po0.0001). The only
other result of interest in the IGF1 gene was a relatively modest
dominant effect of polymorphisms rs35765, rs35767 and rs6220,
resulting in a higher mean circulating IGF-I level, and visible also
in the haplotype analysis.
For the IGFBP3 gene, we observed that a number of previous
studies showed an increase in circulating IGFBP-3 levels associated
with the A allele of a polymorphism in the promoter of IGFBP3
at position  202 (rs2854744) (Pp0.0001). Reflecting the strong
amount of LD in this area (Figure 1B), we also noted a strong
association between increased IGFBP-3 levels and alleles of the
surrounding polymorphisms, rs2132571, rs2132572, rs2471551,
which belong to the same haplotype block (Supplementary Table 2).
The polymorphism P0453 of IGFBP3 also showed a slight
increase in the mean circulating IGF-I protein levels and one
IGFBP3 haplotype showed an increase in risk of breast cancer,
under a recessive model.
Polymorphic variations in the IGFBP1 gene did not show
associations with any of the end points. Homozygous carriers of
the polymorphism rs3751893 in IGFALS, however, showed a
significant reduction in mean circulating IGF-I levels.
DISCUSSION
We have performed a large-scale association study, nested in
the EPIC cohort, to assess the role of genetic variation of IGF1
and of the genes encoding the major IGF-I binding proteins on risk
of breast cancer and on circulating levels of IGF-I and IGFBP-3.
We genotyped 23 SNPs in the four candidate genes. Our criteria
for selecting the SNPs to study were proven existence in the
Caucasian population, high allele frequency and/or high chance
of having an impact on gene expression or function of the
gene product. Our selection of SNPs to be typed was not based
on a formal haplotype tagging approach, because we estimated
that the available information (as of the time of writing this report)
was insufficient to do so accurately. In view of the relative paucity
of publicly available (e.g. HapMap) data, an accurate haplo-
type tagging approach would have required complete resequencing
of the gene region in a sufficient number of subjects, in order to
establish a complete catalogue of polymorphisms and to examine
LD patterns between them. Such effort was beyond the scope
IGF-I-related polymorphisms, IGF-I, IGFBP-3 and breast cancer
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sTable 2 Associations between SNPs and breast cancer risk and mean IGF-I and IGFBP-3 levels adjusted for age and centre
Genotype
Gene SNP Homozygous major Heterozygous Homozygous minor PCodominant
a PDominant
b PRecessive
c
IGF1 rs35765 Cases/controls 609/1148 169/362 17/37
OR (95% CI) 1.00 0.88 (0.72–1.08) 0.86 (0.48–1.54) 0.22 0.21 0.70
Mean IGF-I 244.2 253.6 234.4 0.10 0.02 0.21
Mean IGFBP-3 3379 3412 3371 0.46 0.36 0.87
rs35767 Cases/controls 549/1016 201/432 22/62
OR (95% CI) 1.00 0.86 (0.71–1.05) 0.66 (0.40–1.09) 0.04 0.07 0.15
Mean IGF-I 243.2 252.0 238.0 0.10 0.02 0.32
Mean IGFBP-3 3377 3385 3204 0.25 0.66 0.02
rs2162679 Cases/controls 570/1060 212/446 19/61
OR (95% CI) 1.00 0.88 (0.72–1.06) 0.57 (0.34–0.97) 0.03 0.07 0.05
Mean IGF-I 244.7 251.5 239.3 0.23 0.08 0.35
Mean IGFBP-3 3397 3382 3165 0.04 0.20 0.003
rs6220 Cases/controls 405/813 325/592 59/126
OR (95% CI) 1.00 1.11 (0.92–1.33) 0.95 (0.68–1.32) 0.69 0.39 0.54
Mean IGF-I 247.6 255.2 247.0 0.17 0.03 0.46
Mean IGFBP-3 3420 3395 3363 0.22 0.26 0.38
rs6214 Cases/controls 282/503 366/753 131/271
OR (95% CI) 1.00 0.88 (0.72–1.06) 0.88 (0.68–1.13) 0.22 0.15 0.64
Mean IGF-I 246.7 244.3 244.9 0.56 0.45 0.91
Mean IGFBP-3 3395 3344 3376 0.41 0.15 0.79
IGFALS rs3751893 Cases/controls 546/1085 231/436 21/42
OR (95% CI) 1.00 1.06 (0.88–1.28) 0.98 (0.57–1.67) 0.67 0.59 0.89
Mean IGF-I 251.4 249.8 226.4 0.06 0.23 0.005
Mean IGFBP-3 3420 3375 3305 0.07 0.10 0.24
rs17559 Cases/controls 620/1246 149/256 5/10
OR (95% CI) 1.00 1.17 (0.94–1.46) 1.02 (0.35–2.99) 0.19 0.17 1.00
Mean IGF-I 244.9 248.5 227.9 0.60 0.45 0.32
Mean IGFBP-3 3375 3344 3439 0.53 0.45 0.69
rs2230053 Cases/controls 788/1551 13/16 0/1
OR (95% CI) 1.00 1.64 (0.75–0.36) — 0.37 0.28 —
Mean IGF-I 246.2 248.3 240.1 0.90 0.89 0.93
Mean IGFBP-3 3385 3487 3751 0.35 0.38 0.59
IGFBP1 rs1995051 Cases/controls 413/766 302/627 60/110
OR (95% CI) 1.00 0.89 (0.74–1.07) 1.02 (0.73–1.42) 0.50 0.28 0.67
Mean IGF-I 253.4 256.3 247.1 0.89 0.59 0.17
Mean IGFBP-3 3239 3243 3261 0.74 0.82 0.71
rs1065780 Cases/controls 304/555 356/741 114/207
OR (95% CI) 1.00 0.88 (0.73–1.07) 1.02 (0.78–1.33) 0.71 0.31 0.50
Mean IGF-I 252.9 254.3 255.7 0.52 0.57 0.63
Mean IGFBP-3 3234 3260 3210 0.91 0.61 0.35
rs9658194 Cases/controls 291/521 253/498 25/51
OR (95% CI) 1.00 0.98 (0.81–1.19) 0.95 (0.59–1.55) 0.81 0.83 0.87
Mean IGF-I 253.5 254.2 253.1 0.88 0.84 0.94
Mean IGFBP-3 3222 3281 3264 0.08 0.05 0.78
rs3828998 Cases/controls 291/521 332/686 110/194
OR (95% CI) 1.00 0.87 (0.71–1.05) 1.03 (0.78–1.35) 0.71 0.27 0.42
Mean IGF-I 253.7 253.6 255.6 0.75 0.91 0.64
Mean IGFBP-3 3198 3214 3183 0.93 0.76 0.56
rs3793344 Cases/controls 305/549 350/742 115/203
OR (95% CI) 1.00 0.85 (0.70–1.02) 1.03 (0.79–1.35) 0.66 0.19 0.34
Mean IGF-I 254.0 254.1 255.3 0.82 0.91 0.77
Mean IGFBP-3 3233 3256 3212 0.93 0.64 0.41
rs4988515 Cases/controls 715/1412 62/111 2/6
OR (95% CI) 1.00 1.11 (0.80–1.54) 0.67 (0.13–3.30) 0.72 0.62 0.62
Mean IGF-I 253.9 258.6 239.9 0.57 0.46 0.56
Mean IGFBP-3 3164 3213 3479 0.18 0.25 0.20
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many new common polymorphisms, which were the focus of
our investigation, would have been discovered by systematic
resequencing.
The use of a multicentric study raises the possibility of
confounding by population stratification. Although 97% of
EPIC subjects are estimated to be of Caucasian origin, there could
still be confounding by population stratification if SNP or
haplotype allele frequencies varied between the subject recruit-
ment areas, while at the same time there was also variation in
average breast cancer incidence rates. We did not observe
wide differences in allele frequencies between different countries
in our study (data not shown). In addition, breast cancer cases
and control subjects were systematically matched for the
study centre where they had been recruited into the EPIC
cohorts, and we adjusted all statistical analyses of associa-
tion between SNPs, hormone levels and breast cancer risk
for the factor ‘recruitment centre’. We believe therefore that
confounding by population stratification is not an issue in
our study.
We have found an association with decreased breast cancer risk
of a haplotype located in the 50 part of IGF1. This association was
particularly strong among women younger than 55 years.
No other variant among the ones we studied showed any
association with cancer risk, except for two haplotypes of IGFBP3.
These associations are likely to be chance findings, as they are
based on small numbers.
Our results suggest that in none of the four genes we examined
were there any SNPs that had a strong impact on circulating levels
of IGF-I.
Table 2 (Continued)
Genotype
Gene SNP Homozygous major Heterozygous Homozygous minor PCodominant
a PDominant
b PRecessive
c
rs4619 Cases/controls 347/665 347/698 89/175
OR (95% CI) 1.00 0.95 (0.79–1.15) 0.97 (0.73–1.30) 0.71 0.62 1.00
Mean IGF-I 254.2 253.4 257.4 0.70 0.99 0.43
Mean IGFBP-3 3174 3171 3124 0.41 0.67 0.28
IGFBP3 rs2132571 Cases/controls 393/714 308/674 75/135
OR (95% CI) 1.00 0.83 (0.69–0.99) 1.01 (0.74–1.38) 0.29 0.08 0.50
Mean IGF-I 253.5 253.0 256.8 0.73 0.96 0.49
Mean IFGBP-3 3322 3208 3034 o0.0001 o0.0001 o0.0001
rs2132572 Cases/controls 501/980 234/478 42/59
OR (95% CI) 1.00 0.96 (0.80–1.17) 1.42 (0.94–2.15) 0.47 0.90 0.08
Mean IGF-I 254.2 251.1 274.5 0.30 0.94 0.002
Mean IFGBP-3 3266 3195 3206 0.03 0.02 0.61
rs2854744 Cases/controls 208/407 368/743 200/369
OR (95% CI) 1.00 0.97 (0.79–1.20) 1.08 (0.85–1.38) 0.52 0.92 0.34
Mean IGF-I 259.8 248.8 254.8 0.19 0.01 0.51
Mean IFGBP-3 3101 3246 3389 o0.0001 o0.0001 o0.0001
rs2471551 Cases/controls 485/928 248/508 38/59
OR (95% CI) 1.00 0.92 (0.76–1.12) 1.22 (0.80–1.86) 0.97 0.62 0.29
Mean IGF-I 252.4 254.0 257.8 0.42 0.50 0.50
Mean IFGBP-3 3285 3200 2994 o0.0001 0.0002 0.0002
P0453
d Cases/controls 770/1506 10/29 —
OR (95% CI) 1.00 0.68 (0.33–1.39) — 0.29 0.29 —
Mean IGF-I 253.4 289.5 — 0.001 0.001 —
Mean IFGBP-3 3243 3078 — 0.13 0.13 —
rs2453839 Cases/controls 523/985 236/502 27/59
OR (95% CI) 1.00 0.89 (0.74–1.08) 0.87 (0.55–1.39) 0.22 0.20 0.67
Mean IGF-I 254.1 253.2 255.0 0.90 0.83 0.87
Mean IFGBP-3 3243 3232 3273 0.96 0.81 0.66
P0448
d Cases/controls 566/1116 202/384 14/26
OR (95% CI) 1.00 1.05 (0.86–1.29) 1.07 (0.56–2.06) 0.61 0.61 0.87
Mean IGF-I 255.0 250.5 245.9 0.13 0.15 0.47
Mean IFGBP-3 3233 3272 3270 0.24 0.22 0.80
rs6670 Cases/controls 445/887 287/572 43/61
OR (95% CI) 1.00 1.00 (0.83–1.19) 1.44 (0.95–2.18) 0.35 0.69 0.08
Mean IGF-I 260.7 256.4 254.3 0.12 0.12 0.50
Mean IFGBP-3 3263 3256 3368 0.48 0.87 0.11
aP-value for codominant model (trend).
bP-value for dominant model.
cP-value for recessive model. SNP¼single nucleotide polymorphism; IGF-I¼insulin-like growth factor I;
IGFBP-3¼insulin-like binding protein-3; OR¼odds ratio; CI¼confidence interval. Mean IGF-I and mean IFGBP-3 are means of hormone levels, expressed in ng/ml, for subjects
(cases+controls) belonging to each genotype category, adjusted for age and centre.
dInternal references are used for polymorphisms not present in dbSNP. P-values that reached
statistical significance at the 0.05 level are reported in bold.
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2001), which found that carriers of the less frequent G variant allele
of SNP rs3793344, located in a region of intron 1 of IGFBP1, which
harbours sequences affecting gene expression, had significantly
lower circulating levels of IGF-I both before and after overfeeding.
Subjects carrying two copies of the A allele had lower IGF-I
concentrations before overfeeding, which were further decreased
after overfeeding compared to subjects carrying the rarer G allele.
This may indicate that the AA genotype results in higher IGFBP-1
concentrations, which could decrease available IGF-I. We found no
evidence of higher IGF-I concentrations with this polymorphism.
It is possible that the previously reported association (Ukkola et al,
2001) is linked to the peculiar study conditions (long-term caloric
surplus). Alternatively, the association could be due to a statistical
fluctuation caused by the small sample size of the study (12 pairs
of monozygotic twins).
The finding supported by the strongest statistical evidence in
our study is the association of polymorphisms in the 50 region of
IGFBP3 with circulating levels of IGFBP-3. This association has
been reported in several previous studies, and has been ascribed to
a polymorphism located at position  202 (rs2854744) from the
transcription start site (Deal et al, 2001; Jernstrom et al, 2001b;
Schernhammer et al, 2003). In accordance with these previous
reports, we also found a dose-dependent association of the A allele
with increased levels of circulating IGFBP-3. In addition, we
observed strong associations of all surrounding polymorphisms
with IGFBP-3 levels (Supplementary Table 2). This leads to the
question which of these various polymorphisms would be the
functional polymorphism causing the association with IGFBP-3
levels. In a recent study in vitro, a construct including only the A
allele of the rs2854744 SNP variant was found to increase promoter
activity, suggesting that rs2854744 is the functional variant that
affects IGFBP-3 transcription, and that the associations we have
observed with the other polymorphisms of IGFBP3 are exclusively
due to strong LD (Deal et al, 2001).
The  202 polymorphism also has been studied in relation to
risk of breast cancer (Deal et al, 2001; Schernhammer et al, 2003)
and other cancers (Wang et al, 2003; Li et al, 2004; Slattery et al,
2004). In agreement with most previous studies, we noted no
association between this allele in our series as a whole, or in our
stratified analysis based on age of onset. Probably, the effect of this
polymorphism on circulating IFGBP-3 levels (estimated in 6–9%
of variation) (Jernstrom et al, 2001b; Schernhammer et al, 2003) is
not sufficient, by itself, to alter amounts of bioavailable IGF-I
sufficiently to lead to a substantial change in cancer risk. In one
recent study, however, the C allele of the  202 polymorphism was
found to be associated with more advanced disease status in
prostate cancer, even though it was not associated with prostate
cancer risk overall (Wang et al, 2003).
Besides polymorphic variation in the IGFBP3 gene, another strong
predictor of variability in IGFBP-3 levels was the same IGF1
haplotype that was associated, in the same direction, with cancer
risk. This was particularly evident when the analysis was restricted
to the haplotypes observed within the strong LD block in the 50
region of the gene. It is difficult to interpret these associations, with
either IGFBP-3 levels or cancer risk, as for none of these SNPs is
there any evidence to suggest a possible functional role. Little
appears to be known about what genomic elements are involved in
the regulation of IGF1 transcription, except for a region immediately
upstream of the transcription start (Porcu et al, 1994; Rubini et al,
1994), which however harbours no known genetic variation. We
have not typed a CA repeat polymorphism located in the 50 region
of IGF1, between SNPs rs35767 and rs2162679, which has been
frequently included in previous studies. Several epidemiological
studies on the association between this polymorphism and breast
cancer risk or IGF-I levels (Jernstrom et al, 2001a; Yu et al,2 0 0 1 ;
Figer et al, 2002; Missmer et al,2 0 0 2 ;D e L e l l i set al, 2003) have
yielded highly conflicting results. This microsatellite polymorphism
has a large number of alleles, which results in fractioning the study
population into a large number of classes. Even with a large sample
size, this makes statistical analysis very difficult. Moreover, there are
no studies that show a functional role for this microsatellite. We
b e l i e v et h a ti ti su n l i k e l yt h a tt h eIGF1 CA repeat has a functional
role of its own, and that associations previously reported with this
microsatellite are likely to reflect LD with the same SNPs that we
included in our study or with other, yet unknown SNPs located in
the region. In any case, the level of LD in the 50 region of the gene is
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Figure 1 (A) Graphical representation of LD and block structure of
IGF1.( B) Graphical representation of LD and block structure of IGFBP3.
The upper bars represent SNPs and physical distances among them.
Numbers within squares are pairwise D0 values. Absence of value means
D0 ¼1. The colour code shows confidence boundaries of LD estimations:
black shows evidence of LD, white shows evidence of recombination and
grey shows uninformative pairs. Linkage disequilibrium blocks were defined
according to the algorithm of Gabriel et al (2002). Internal references are
used for polymorphisms not present in dbSNP.
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single out one particular variant as that causing variation in IGFBP-3
levels and, possibly, cancer risk. Moreover, genetic variation in the
promoter of IGF1 should have an impact on circulating IGFBP-3
only through a modification of circulating IGF-I, which we observe
only at modest levels. Functional studies will be needed to clarify
this point.
Other polymorphic variants that were found to be associated
with IGFBP-3 levels – a haplotype in the 50 region of IGF1,i n
homozygosity, and SNP rs3751893 of IGFALS – are difficult to
evaluate, because of the small number of subjects carrying the
alleles that showed the associations.
In summary, the main findings of our study were thus a weak
but nominally significant association of a block of polymorphisms
located at the 50 end of the IGF1 gene with breast cancer risk,
particularly among women younger than 55 years, and an
association of polymorphisms located in the 50 region of IGFBP3
with circulating levels of IGFBP-3. The large number of statistical
tests we have performed raises the issue of potential false positives.
An alternative to applying a Bonferroni’s correction, which is
generally too conservative because of statistical dependence
between tests for multiple SNPs that are in LD, is the use of a
Bayesian approach, such as the recently introduced calculation of
FPRP (Wacholder et al, 2004). Given the absence of previous
functional or epidemiologic data on the IGF1 SNPs we found
associated with breast cancer risk, we calculated FPRPs by using a
prior probability of true association. Calculated FPRPs were high
even with a relatively high prior probability of 0.01 that variants
would have an association with breast cancer risk or with
circulating peptide levels. Our finding relating IGFBP3 SNPs with
serum IGFBP-3 levels, however, is strongly backed by previous
epidemiologic and functional findings and is also supported by
very low P-values in our study, and resulted in very low FPRPs
over a wide range of prior probabilities of true association.
In conclusion, our results show a number of genetic variants
associated with circulating hormone levels, including a convincing
association of IGFBP3 SNPs with IGFBP-3 levels. On the other hand,
we have found only weak or no associations of genetic variants in
IGF1, IGFBP1, IGFBP3 and IGFALS with breast cancer risk, and
further large studies will be required to confirm our findings.
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